<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.4 20241031//EN" "https://jats.nlm.nih.gov/archiving/1.4/JATS-archive-oasis-article1-4-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.4" article-type="research-article" xml:lang="en"><front><journal-meta><journal-title-group><journal-title xml:lang="ru">Российский внешнеэкономический вестник</journal-title></journal-title-group><issn publication-format="print">2072-8042</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.64545/2072-8042-2025-9-25-41</article-id><article-categories><subj-group><subject>Other</subject></subj-group></article-categories><title-group><article-title xml:lang="ru">Защита интеллектуальной собственности в фармацевтической отрасли ЕС и глобальный доступ к лекарствам</article-title><trans-title-group xml:lang="en"><trans-title>INTELLECTUAL PROPERTY PROTECTION IN THE EU PHARMACEUTICAL INDUSTRY AND GLOBAL ACCESS TO MEDICINES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Гусейнов</surname><given-names>Элсун Элварович</given-names></name><name xml:lang="en"><surname>Guseinov</surname><given-names>Elsun Elvarovich</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/><email>elsun.gusejnov@list.ru</email><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0139-0365</contrib-id></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Исаченко</surname><given-names>Татьяна Михайловна</given-names></name><name xml:lang="en"><surname>Isachenko</surname><given-names>Tatiana Mikhailovna</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff5"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff6"/><email>isachenko_tatiana@mail.ru</email><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5051-6249</contrib-id></contrib><aff-alternatives id="aff1"><aff><institution xml:lang="en">MGIMO University</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">United Metallurgical Company (JSC “OMK”)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="ru">МГИМО МИД России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="ru">Объединённая металлургическая компания (АО «ОМК»)</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Russian Foreign Trade Academy</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="ru">Всероссийская академия внешней торговли</institution></aff></aff-alternatives></contrib-group><pub-date pub-type="epub" iso-8601-date="2025-12-11"><day>11</day><month>12</month><year>2025</year></pub-date><issue>9</issue><fpage>25</fpage><lpage>41</lpage><permissions><license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xlink:title="CC BY-NC 4.0"><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p xml:lang="ru">CC BY-NC 4.0</license-p></license></permissions><self-uri xlink:href="https://journal.vavt.ru/rfej/article/view/2772" xlink:title="https://journal.vavt.ru/rfej/article/view/2772">https://journal.vavt.ru/rfej/article/view/2772</self-uri><self-uri content-type="pdf" xlink:href="publication-ea6f8be6-d23e-4f9b-96fe-f04a8e827ccc.pdf" xlink:title="PDF"/><abstract xml:lang="ru"><p>В статье проводится комплексный анализ торговой политики Европейского Союза в сфере фармацевтики, исследуется ее двойственное влияние на глобальный рынок. Рассматривается диалектическое противоречие между целями стимулирования фармацевтических инноваций посредством усиленной защиты интеллектуальной собственности (ИС) и задачей обеспечения глобального доступа к лекарственным средствам. На основе анализа Соглашения ТРИПС и регуляторных инструментов ЕС, включая положения «ТРИПС-плюс», выявляется стратегия экспорта нормативной модели ЕС. Количественный анализ торговых потоков и исследование казуса торговых отношений ЕС и Индии демонстрируют практические последствия этой политики.</p></abstract><abstract xml:lang="en" abstract-type="summary"><p>The article provides a comprehensive analysis of the European Union’s trade policy in the pharmaceutical sector, exploring its dual impact on the global market. It examines the dialectical contradiction between the objectives of stimulating pharmaceutical innovation through enhanced intellectual property (IP) protection and ensuring global access to medicines. Based on an analysis of the TRIPS Agreement and EU regulatory instruments, including “TRIPS-plus” provisions, the EU’s strategy of exporting its normative model is identified. A quantitative analysis of trade flows and a case study of EU-India trade relations demonstrate the practical consequences of this policy.</p></abstract><kwd-group xml:lang="ru"><kwd>ДОСТУП К ЛЕКАРСТВАМ,</kwd><kwd>ТОРГОВАЯ ПОЛИТИКА,</kwd><kwd>ЕВРОПЕЙСКИЙ СОЮЗ,</kwd><kwd>ИНТЕЛЛЕКТУАЛЬНАЯ СОБСТВЕННОСТЬ,</kwd><kwd>ФАРМАЦЕВТИКА,</kwd><kwd>СОГЛАШЕНИЕ ТРИПС,</kwd><kwd>МЕЖДУНАРОДНАЯ ТОРГОВЛЯ,</kwd><kwd>ВТО,</kwd><kwd>РАЗВИВАЮЩИЕСЯ СТРАНЫ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>TRADE POLICY,</kwd><kwd>EUROPEAN UNION,</kwd><kwd>INTELLECTUAL PROPERTY,</kwd><kwd>PHARMACEUTICALS,</kwd><kwd>TRIPS AGREEMENT,</kwd><kwd>ACCESS TO MEDICINES,</kwd><kwd>INTERNATIONAL TRADE,</kwd><kwd>WTO,</kwd><kwd>DEVELOPING COUNTRIES</kwd></kwd-group></article-meta></front><back><ref-list><ref id="ref1"><mixed-citation publication-type="other" xml:lang="ru">Лихачёв В. А. Современное состояние защиты прав интеллектуальной собственности в ЕС // Российский внешнеэкономический вестник. 2024. № 5. С. 80-88. @@ Lixachyov V. A. Sovremennoe sostoyanie zashhity` prav intellektual`noj sobstvennosti v ES // Rossijskij vneshnee`konomicheskij vestnik. 2024. № 5. S. 80-88. URL: https://journal.vavt.ru/rfej/article/view/1116/1035 (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="other" xml:lang="ru">Соглашение по торговым аспектам прав интеллектуальной собственности (ТРИПС) // Официальный сайт ВТО. @@ Soglashenie po torgovy`m aspektam prav intellektual`noj sobstvennosti (TRIPS) // Oficial`ny`j sajt VTO. URL: https://www.wto.org/english/docs_e/legal_e/27-trips.pdf (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="other" xml:lang="ru">Шугуров М. В. Европейский союз и защита прав интеллектуальной собственности в третьих странах // Современная Европа. - 2022. - № 1. - С. 125-138. @@ Shugurov M. V. Evropejskij soyuz i zashhita prav intellektual`noj sobstvennosti v tret`ix stranax // Sovremennaya Evropa. - 2022. - № 1. - S. 125-138. - DOI: 10.31857/S0201708322010107 URL: http://www.sov-europe.ru/images/pdf/2022/1-2022/Shugurov-1-22.pdf (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="other" xml:lang="ru">Шумпетер Й. А. Теория экономического развития. Капитализм, социализм и демократия. - М.: Эксмо, 2007. - 864 с. @@ Shumpeter J. A. Teoriya e`konomicheskogo razvitiya. Kapitalizm, socializm i demokratiya. - M.: E`ksmo, 2007. - 864 s.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="other" xml:lang="en">10 Key Differences Between U.S. and European Patent Systems - PatentPC URL: https://patentpc.com/blog/10-key-differences-between-u-s-and-european-patent-systems (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="other" xml:lang="en">An international agreement on pandemic prevention, preparedness and response - Public Health - European Commission. URL: https://health.ec.europa.eu/internationalcooperation/global-health/international-agreement-pandemic-prevention-preparedness-and-response_en (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="other" xml:lang="en">Biotech Patent Protection: US vs Europe vs Asia Key Differences - Patsnap Synapse, URL: https://synapse.patsnap.com/article/biotech-patent-protection-us-vs-europe-vs-asia-key-differences (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="other" xml:lang="en">Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options - Duke Law Scholarship Repository. URL: https://scholarship.law.duke.edu/cgi/viewcontent.cgi?arti-cle=2747&amp;context=faculty_scholarship (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="other" xml:lang="en">Differences between Intellectual Property Protection in China and the EU. URL: https://www.ecovis.com/focus-china/differences-intellectual-property-protection-china-eu/ (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="other" xml:lang="en">EU trade in pharmaceutical products - recent developments // Eurostat. - April 2024. URL: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=EU_trade_in_pharmaceutical_products_-_recent_developments (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="other" xml:lang="en">Eurostat. Medicinal and pharmaceutical products: Exports down in 2023. URL: https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20240426-3 (дата обращения 01.05.2025).</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="other" xml:lang="en">Global Pharmaceuticals Market Report 2024 // The Business Research Company. - January 2024. URL: https://www.thebusinessresearchcompany.com/report/pharmaceuticals-globalmarket-report (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="other" xml:lang="en">Indian Generic Medicines: The ‘Pharmacy of the Developing World’ // The India Brand Equity Foundation (IBEF). - May 2024. URL: https://www.ibef.org/blogs/indian-generic-medicines-the-pharmacy-of-the-developing-world (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="other" xml:lang="en">Perehudo , K., et al. Impact of the European Union on access to medicines in low-and middle-income countries: A scoping review //The Lancet Regional Health - Europe. - 2021. - Vol.9. - 100219.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="other" xml:lang="en">Submission by the Group for Equity: Outline &amp; key elements for annex on WHO pathogen access and benefit sharing system (PABS System) / Group for Equity. - Geneva: World Health Organization, [2025]. - 8 p. URL: https://apps.who.int/gb/igwg/pdf_files/IGWG2-initial-text-proposals/Group_for_Equity.pdf (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="other" xml:lang="en">The Global Patent Thicket: A Comparative Analysis of Pharmaceutical Monopoly Strategies in the U.S., Europe, and Emerging Markets. URL: https://www.drugpatentwatch.com/blog/how-do-patent-thickets-vary-across-different-countries/ (дата обращения 02.09.2025).</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="other" xml:lang="en">Trading away health: How the EU-Vietnam trade deal threatens access to medicines // Oxfam International. - January 2019. URL: https://www.oxfam.org/en/research/trading-away-health (дата обращения: 02.07.2025).</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="other" xml:lang="en">Wouters O. J., McKee M., Luyten J. Estimated Research and Development Investment to Bring a New Medicine to Market, 2009-2018 //JAMA. - 2020. - Vol. 323, No. 9. - P. 844-853.</mixed-citation></ref></ref-list><ack xml:lang="ru"><p>Подготовлено в рамках выполнения государственного задания ВАВТ Минэкономразвития России</p></ack></back></article>
